Clinical trial

Evaluation Study of New Compounds With Potential Use in Schizophrenia

NCT00916201

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention URB597 Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention intranasal Insulin Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Cannabidiol CR Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Evaluation Study of New Compounds With Potential Use in Schizophrenia

Design: INTERVENTIONAL · Status: WITHDRAWN · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusWITHDRAWN

Study typeINTERVENTIONAL

Start date2025-01-31

PhasePHASE1

Conditions

Schizophreniaverified · MONDO: schizophrenia

Interventions

URB597DRUG

intranasal InsulinDRUG

Cannabidiol CRDRUG

Sponsors & collaborators

Central Institute of Mental Health, Mannheimlead sponsor

Max Planck Institute for Metabolism Researchcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00916201 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.